scholarly journals A case of advanced gastric cancer with multiple liver metastases successfully treated with post operative intrahepatic chemotherapy and oral administration of 5'-deoxy-5-fluorouridine.

2000 ◽  
Vol 61 (10) ◽  
pp. 2647-2651
Author(s):  
Hiroshi NAKASHIMA ◽  
Yoshihiko HAYASHI ◽  
Kouichi FURUGAKI ◽  
Hidekazu NISHINAKA ◽  
Takahito KASHIWAGI
Keyword(s):  
Gastric Cancer ◽  
Oral Administration ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Multiple Liver Metastases

scholarly journals Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment

In Vivo ◽  
2021 ◽  
Vol 35 (5) ◽  
pp. 2929-2935
Author(s):  
TSUTOMU NAMIKAWA ◽  
AKIRA MARUI ◽  
KEIICHIRO YOKOTA ◽  
YUKI FUJIEDA ◽  
MASAYA MUNEKAGE ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Combination Treatment ◽  
Conversion Surgery ◽  
Multiple Liver Metastases

scholarly journals Ramucirumab combined with paclitaxel as the second-line chemotherapy for elderly patients with disseminated gastric cancer

2018 ◽  
pp. 169-171
Author(s):  
T. A. Titova ◽  
N. S. Besova ◽  
V. A. Gorbunova ◽  
R. N. Nasyrova ◽  
A. A. Fedenko
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Metastatic Gastric Cancer ◽  
Phase Iii ◽  
Second Line ◽  
Her2 Positive ◽  
Second Line Chemotherapy ◽  
Multiple Liver Metastases ◽  
Line Chemotherapy

Gastric cancer is the third leading cause of cancer-related deaths worldwide. The prognosis of advanced gastric cancer remains poor despite therapeutic advances in recent decades. Several recent positive phase III trials established the efficacy of second-line chemotherapy for metastatic gastric cancer in prolonging overall survival. Many targeted-therapies failed to show a significant survival benefit in GC, only 2 of them are approved FDA: trastuzumab in the 1-st line treatment of HER2-positive gastric cancer and ramucirumab with or without paclitaxel as second line chemotherapy. The article presents the case of effective treatment of patient with Her2-negative advanced gastric cancer. A 76-year-old man had a moderately differentiated adenocarcinoma of gastric with synchronous multiple liver metastases. He received ramucirumab with paclitaxel as second -line chemotherapy. The size of the liver metastases was reduced and he maintained a partial response for one year. This clinical case report demonstrates that new option in the treatment of advanced gastric cancer can to allow our patients to live longer without losing the quality of life.

Combination chemotherapy with mitomycin C and cisplatin for advanced gastric cancer with multiple liver metastases

Surgery Today ◽  
1994 ◽  
Vol 24 (9) ◽  
pp. 819-822 ◽  
Author(s):  
Yoshiro Saikawa ◽  
Tetsuro Kubota ◽  
Toshiharu Furukawa ◽  
Koichiro Kumai ◽  
Keiichi Yoshino ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Mitomycin C ◽  
Combination Chemotherapy ◽  
Multiple Liver Metastases

scholarly journals Long-Term Survival of Two Patients with Liver Metastases from Advanced Gastric Cancer Treated with Radiofrequency Ablation and Chemotherapy

2021 ◽  
pp. 67-72
Author(s):  
Sung Jin Oh
Keyword(s):  
Gastric Cancer ◽  
Radiofrequency Ablation ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Systemic Chemotherapy ◽  
Subtotal Gastrectomy ◽  
Hepatic Metastases ◽  
Term Survival ◽  
Long Term Survival

Liver metastasis from gastric cancer has a very poor prognosis. Herein, we present two cases of liver metastases (synchronous and metachronous) from advanced gastric cancer. In the first case, the patient underwent radical subtotal gastrectomy. Liver metastases occurred 6 months after surgery while the patient was receiving adjuvant chemotherapy, but two hepatic tumors were successfully removed by radiofrequency ablation (RFA). In the second case, liver metastases occurred 15 months after surgery for gastric cancer. The patient also received RFA for one hepatic tumor, and other suspicious metastatic tumors were treated with systemic chemotherapy. Although these case presentations are limited for the efficacy of RFA treatment with systemic chemotherapy for hepatic metastases from gastric cancer, our findings showed long-term survival (overall survival for 108 and 67 months, respectively) of the affected patients, without recurrence. Therefore, we suggest that RFA treatment with systemic chemotherapy could be an effective alternative treatment modality for hepatic metastases from gastric cancer.

scholarly journals A Case of AFP Producing Gastric Cancer with Multiple Liver Metastases Successfully Treated with Low Dose FAP Via Hepatic Artery

2002 ◽  
Vol 27 (6) ◽  
pp. 902-907
Author(s):  
Toshio TAKAYAMA ◽  
Masahiko SUGANO ◽  
Toshiki KAMANO ◽  
Masahiko TURUMARU ◽  
Yasuo HAYASHIDA ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Hepatic Artery ◽  
Low Dose ◽  
Multiple Liver Metastases

scholarly journals Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report

2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Yoichi Hamai ◽  
Jun Hihara ◽  
Manabu Emi ◽  
Yoshiro Aoki ◽  
Kei Kushitani ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Case Report ◽  
Liver Metastases ◽  
Sigmoid Colon ◽  
Multiple Liver Metastases
Sign in / Sign up

Export Citation Format

Share Document